BACKGROUND: After ischemia/reperfusion (I/R) injury, female hearts demonstrate improved functional recovery compared with male, which suggests a protective role for estrogen. Acute postischemic treatment with 17-beta-estradiol (E2) attenuates myocardial dysfunction. However, it is unknown by which estrogen receptor (ER) E2 mediates this acute cardioprotection during I/R. Therefore, we hypothesize that postischemic infusion of the selective ER-alpha agonist (4,4',4''-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol [PPT]) or the selective ER-beta agonist (2,3-bis(4-hydroxyphenyl)-propionitrile [DPN]) will improve myocardial function after I/R injury. METHODS: Isolated, perfused hearts (Langendorff) from adult male rats were subjected to 25 minutes of ischemia followed by 40 minutes of reperfusion. Hearts (n = 4-6 per group) were randomly infused with either perfusate, PPT or DPN at 1, 10, or 100 nmol/L throughout reperfusion. After I/R, heart tissue was analyzed for tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, vascular endothelial growth factor (VEGF), and lactate dehydrogenase (LDH). RESULTS: Postischemic treatment with 10 nmol/L of PPT significantly improved myocardial function. Additionally, 10 or 100 nmol/L of DPN significantly increased myocardial functional recovery after I/R injury, with maximum benefit at the 10 nmol/L dose. A trend toward lower levels of LDH was noted in DPN- and PPT-treated groups after I/R injury. Neither PPT nor DPN affected myocardial production of TNF-alpha or IL-1beta. However, higher levels of myocardial VEGF were noted in the PPT-treated group compared with controls. CONCLUSION: Both ER-alpha and ER-beta are involved in mediating E2-induced rapid cardioprotection after I/R injury. Advancing our understanding of both ER subtypes may be useful for the development of novel strategies that may benefit both males and females in response to myocardial ischemia.
BACKGROUND: After ischemia/reperfusion (I/R) injury, female hearts demonstrate improved functional recovery compared with male, which suggests a protective role for estrogen. Acute postischemic treatment with 17-beta-estradiol (E2) attenuates myocardial dysfunction. However, it is unknown by which estrogen receptor (ER) E2 mediates this acute cardioprotection during I/R. Therefore, we hypothesize that postischemic infusion of the selective ER-alpha agonist (4,4',4''-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol [PPT]) or the selective ER-beta agonist (2,3-bis(4-hydroxyphenyl)-propionitrile [DPN]) will improve myocardial function after I/R injury. METHODS: Isolated, perfused hearts (Langendorff) from adult male rats were subjected to 25 minutes of ischemia followed by 40 minutes of reperfusion. Hearts (n = 4-6 per group) were randomly infused with either perfusate, PPT or DPN at 1, 10, or 100 nmol/L throughout reperfusion. After I/R, heart tissue was analyzed for tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, vascular endothelial growth factor (VEGF), and lactate dehydrogenase (LDH). RESULTS: Postischemic treatment with 10 nmol/L of PPT significantly improved myocardial function. Additionally, 10 or 100 nmol/L of DPN significantly increased myocardial functional recovery after I/R injury, with maximum benefit at the 10 nmol/L dose. A trend toward lower levels of LDH was noted in DPN- and PPT-treated groups after I/R injury. Neither PPT nor DPN affected myocardial production of TNF-alpha or IL-1beta. However, higher levels of myocardial VEGF were noted in the PPT-treated group compared with controls. CONCLUSION: Both ER-alpha and ER-beta are involved in mediating E2-induced rapid cardioprotection after I/R injury. Advancing our understanding of both ER subtypes may be useful for the development of novel strategies that may benefit both males and females in response to myocardial ischemia.
Authors: Meijing Wang; Lauren Baker; Ben M Tsai; Kirstan K Meldrum; Daniel R Meldrum Journal: Am J Physiol Endocrinol Metab Date: 2004-09-14 Impact factor: 4.310
Authors: Richard D Patten; Isaac Pourati; Mark J Aronovitz; Jason Baur; Flore Celestin; Xin Chen; Ashour Michael; Syed Haq; Simone Nuedling; Christian Grohe; Thomas Force; Michael E Mendelsohn; Richard H Karas Journal: Circ Res Date: 2004-09-02 Impact factor: 17.367
Authors: G B Stefano; V Prevot; J C Beauvillain; P Cadet; C Fimiani; I Welters; G L Fricchione; C Breton; P Lassalle; M Salzet; T V Bilfinger Journal: Circulation Date: 2000-04-04 Impact factor: 29.690
Authors: D Camper-Kirby; S Welch; A Walker; I Shiraishi; K D Setchell; E Schaefer; J Kajstura; P Anversa; M A Sussman Journal: Circ Res Date: 2001-05-25 Impact factor: 17.367
Authors: Fawzi A Babiker; Leon J De Windt; Martin van Eickels; Christian Grohe; Rainer Meyer; Pieter A Doevendans Journal: Cardiovasc Res Date: 2002-02-15 Impact factor: 10.787
Authors: Meijing Wang; Paul R Crisostomo; Troy Markel; Yue Wang; Keith D Lillemoe; Daniel R Meldrum Journal: Surgery Date: 2008-05-09 Impact factor: 3.982
Authors: Andrea L Portbury; Sarah M Ronnebaum; Makhosazane Zungu; Cam Patterson; Monte S Willis Journal: J Mol Cell Cardiol Date: 2011-11-06 Impact factor: 5.000